Suggestions
Longsha Liu
CEO, Co-Founder at Vita Innovations - Knight Hennessy Scholar and MD Candidate at Stanford University - Clinton Global Initiative Fellow - Cornell Rawlings Presidential Scholar
Longsha Liu is an accomplished individual with a strong passion for integrating medicine, engineering, and entrepreneurship to improve patient care through technology and research-driven approaches.
Having graduated Phi Beta Kappa from Cornell University with a Bachelor's in Neurobiology and a minor in business for life sciences, Longsha has a solid educational background.
During his time at Cornell, he co-founded and led the Cornell Biomedical Device team, focusing on developing innovative solutions for medical challenges.
As a SENS Research Fellow at Harvard Medical School, Longsha concentrated on designing novel therapeutic approaches for glioblastoma by modulating the gut microbiome.
Additionally, Longsha serves as the CEO and Co-Founder of Vita Innovations, a MedTech startup dedicated to enhancing emergency medicine through patient monitoring solutions and telemedicine applications.
His accolades include being a Clinton Global Initiative Fellow, Cornell Hunter Rawlings Presidential Research Scholar, and recipient of prestigious awards like the Student Business of the Year and Verizon-CGIU Social Innovation Awards.
Longsha's diverse professional experience includes roles such as TA for Biochemistry at Cornell University, Head Undergraduate TA for Intro to Neurobiology, and Founder of the Cornell Chess Outreach Program.
He has also contributed to various research projects at institutions like Harvard Medical School, Tulane Medical Center, Louisiana Cancer Research Center, and Cornell University College of Veterinary Medicine.
With a background in neurobiology, biomedical devices, and startup entrepreneurship, Longsha Liu is poised to make significant strides in healthcare innovation and patient care enhancement.
His interests span across neuroscience and surgical research, microbiome innovation, biomedical devices, entrepreneurship, and machine learning applications.
Highlights
The last few years have been incredibly exciting and pivotal for innovation in medicine. The advent of Generative AI has prompted a crucial reassessment of traditional paradigms within healthcare education, policy, regulation, research, and technology design. In this explorative context, I am thrilled to co-teach "MED 216: Generative AI and Medicine" at Stanford University School of Medicine alongside Justin Norden, MD, MBA, MPhil and Bryant Lin this year. This course has quickly become one of the most popular electives at the medical school, attracting students from diverse fields including medicine, business, and engineering. Each week, we explore the latest developments in the field and host world leaders from academia, industry, venture capital, and government to share their insights and experiences.
Last week, we had the privilege of hosting John Hennessy, Chairman of Alphabet and former President of Stanford. John is such an inspiring and exemplary leader whom I greatly admire and respect, so this session has been incredibly delightful learning from his stories and insights. I’d love to share the most salient key takeaways that I got from the session with the broader community:
• In discussing the role of education in the context of rapidly evolving AI technologies, John emphasized the importance of preparing students to be lifelong learners. The role of an educational system is to equip students not just with specific knowledge, but with the confidence needed to fearlessly adapt and learn new skills as they encounter new areas throughout their careers. • As AI begins to disrupt job markets, notably affecting middle-tier jobs more quickly than historical technological shifts, this need for ongoing education and skill adaptation becomes crucial. One of the first sectors to go will likely be customer service as AI can do it better, faster, and cheaper. • Regulating generative AI is very challenging due to its dual nature as both a tool and software and its potential for both beneficial and harmful uses. There are unfortunately no easy answers when it comes to navigating international differences in trust and antitrust laws or addressing complex copyright and data usage concerns. • We’re not close to Artificial General Intelligence (AGI) but we’re progressing at a faster-than-expected pace. Current LLMs will not be the sole basis for AGI. Future AGI systems are likely to be a hybrid of various models, including less dense models and other neural networks, working in concert to perform complex tasks.
Quick hit questions: • Magic wand in healthcare: “Bend the cost curve” • Contrarian truth: "Individuals can change the world." • Key advice: "Remain intellectually curious for your entire life."
